Gelesis Holdings, Inc.
NYSE: GLS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yishai Zohar
- Employees
- 93
- Headquarters
- Boston, United States
- IPO year
- 2022
- Market cap
- $11.6M
- Website
- https://www.gelesis.com
Loading GLS…
Loading profile data…Frequently asked questions about GLS
What does Gelesis Holdings, Inc. (GLS) do?
Gelesis Holdings Inc. is a biopharmaceutical company actively marketing products, dedicated to creating biomimetic solutions that target the underlying causes of obesity and chronic gastrointestinal conditions. Among its key offerings is PLENITY, an oral therapeutic designed for weight management that is non-stimulant and does not enter the bloo...
Where does GLS trade?
Gelesis Holdings, Inc. (GLS) trades on the New York Stock Exchange.
What sector is GLS in?
Gelesis Holdings, Inc. (GLS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Gelesis Holdings, Inc.?
Yishai Zohar is the chief executive officer of Gelesis Holdings, Inc. (GLS).
Where is Gelesis Holdings, Inc. headquartered?
Gelesis Holdings, Inc. is headquartered in United States.
Does GLS pay a dividend?
Gelesis Holdings, Inc. (GLS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GLS go public?
Gelesis Holdings, Inc. (GLS) completed its initial public offering in 2022.